Abstract
Glutamate is thought to serve as a major excitatory neurotrans-mitter throughout the central nervous system (CNS)1,2; electrophysiological studies indicate that its action is mediated by multiple receptors. Four receptors have been characterized by their selective sensitivity to N-methyl-D-aspartate (NMDA), kainic acid (KA), quisqualic acid (QA) and 2-amino-4-phosphonobutyric acid (APB)1,3–5. Electrophysiological evidence indicates that these receptors are all present in the rat hippocampus and that the anatomically discrete synaptic fields within the hippocampus exhibit differential sensitivity to the selective excitatory amino acid agents3,6,7. Thus, we have used the hippocampus as a model system to investigate possible subpopulations of 3H-L-glutamate binding sites. By using quantitative autoradiography, the pharmacological specificity of 3H-L-glutamate binding in discrete terminal fields was determined. We report here that there are at least four distinct classes of 3H-L-glutamate binding sites which differ in their anatomical distribution, pharmacological profile and regulation by ions. Two of these sites seem to correspond to the KA and NMDA receptor classes, and a third site may represent the QA receptor. The fourth binding site does not conform to present receptor classifications. None of these binding sites corresponds to the major glutamate binding site observed in biochemical studies8–12.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Watkins, J. C. & Evans, R. H. A. Rev. Pharmac. Tox. 21, 165–204 (1981).
Cotman, C. W., Foster, A. C. & Lanthorn, T. in Glutamate as a Neurotransmitter (eds DiChiara, G. & Gessa, G. L. ) 1–27 (Raven, New York, 1981).
Koerner, J. F. & Cotman, C. W. Brain Res. 216, 192–198 (1981).
Evans, R. H., Francis, A. A., Jones, A. W., Smith, D. A. S. & Watkins, J. C. Br. J. Pharmac. 75, 65–75 (1982).
Slaughter, M. M. & Miller, R. F. Science 211, 182–185 (1981).
Robinson, J. H. & Deadwyler, S. A. Brain Res. 221, 117–127 (1981).
Collinridge, G. L., Kehl, S. J. & McLennen, H. J. Physiol., Lond. 334, 19–31 (1983).
Foster, A. C. & Roberts, P. J. J. Neurochem. 31, 1467–1477 (1978).
Baudry, M. & Lynch, G. S. J. Neurochem. 36, 811–820 (1981).
Fagg, G. E., Foster, A. C., Mena, E. E. & Cotman, C. W. J. Neurosci. 2, 958–965 (1982).
Werling, L. L. & Nadler, J. V. J. Neurochem. 38, 1050–1062 (1982).
Fagg, G. E., Foster, A. C., Mena, E. E. & Cotman, C. W. Eur. J. Pharmac. 88, 105–110 (1983).
Fagg, G. E., Mena, E. E., Monaghan, D. T. & Cotman, C. W. Neurosci. Lett. 38, 157–162 (1983).
Foster, A. C., Mena, E. E., Monaghan, D. T. & Cotman, C. W. Nature 289, 73–75 (1981).
Monaghan, D. T. & Cotman, C. W. Brain Res. 252, 91–100 (1982).
Unnerstall, J. R. & Wamsley, J. K. Eur. J. Pharmac. 86, 361–371 (1983).
Simon, J. R., Contrera, J. F. & Kuhar, M. J. J. Neurochem. 26, 141–147 (1976).
London, E. D. & Coyle, J. T. Molec. Pharmac. 15, 492–505 (1979).
Slevin, J. T., Collins, J. F. & Coyle, J. T. Brain Res. 265, 169–172 (1983).
Mena, E. E., Fagg, G. E. & Cotman, C. W. Brain Res. 243, 378–381 (1982).
Whittemore, S. R., Mena, E. E., Monaghan, D. T. & Cotman, C. W. Brain Res. (in the press).
Monaghan, D. T., McMills, M. C., Chamberlin, A. R. & Cotman, C. W. Brain Res. (in the press).
Beaumont, K. et al. Life Sci. 24, 809–816 (1979).
Storm-Mathisen, J. & Iversen, L. L. Neuroscience 4, 1237–1253 (1979).
Roberts, P. J. Nature 252, 399–401 (1974).
Vincent, S. R. & McGeer, E. G. Brain Res. 184, 99–108 (1980).
Balcar, V. J. & Johnston, G. A. R. J. Neurochem. 19, 2657–2666 (1972).
Roberts, P. J. & Watkins, J. C. Brain Res. 85, 120–125 (1975).
Evans, R. H., Francis, A. A., Hunt, K., Oakes, D. J. & Watkins, J. C. Br. J. Pharmac. 67, 591–603 (1979).
Davies, J. & Watkins, J. C. J. Physiol., Lond. 332, 108P–109P (1982).
Nitsch, C. in Amino Acid Neurotransmitters (eds DeFeudis, F. V. & Mandel, P. ) 97–104 (Raven, New York, 1981).
Storm-Mathisen, J. et al. Nature 301, 517–520 (1983).
Altshuler, R. A. et al. Neurosci. Abstr. 8, 663 (1982).
Sloviter, R. S. & Damiano, B. P. Neurosci. Lett. 24, 279–284 (1981).
Cotman, C. W. & Nadler, J. V. in Glutamate: Transmitter in the Central Nervous System (eds Roberts, P. J., Storm-Mathisen, J. & Johnston, G. A. R. ) 117–154 (Wiley, New York, 1981).
Koerner, J. F. & Cotman, C. W. Brain Res. 251, 105–115 (1982).
Storm-Mathisen, J. Prog. Neurobiol. 8, 119–181 (1977).
Schwartz, R., Whetsell, W. O. Jr & Foster, A. C. in Excitoxins (eds Fuxe, K., Roberts, P. J. & Scharcz, R. ) (Pergamon, Oxford, in the press).
Collingridge, G. L., Kehl, S. J. & McLennan, H. J. Physiol., Lond. 334, 33–46 (1983).
Krogsgaard-Larsen, P., Honore, T., Hansen, J. J., Curtis, D. R. & Lodge, E. Nature 284, 64–66 (1980).
Young, W. S. & Kuhar, M. J. Brain Res. 179, 255–270 (1979).
Unnerstall, J. R., Niehoff, D. L., Kuhar, M. J. & Palacios, J. M. J. Neurosci. Meth. 6, 59–73 (1982).
Altar, C. A., Walter, R. J. Jr, Neve, K. A. & Marshall, J. F. Neurosci. Abstr. 9, 1113 (1983).
Greenamyre, J. T., Penny, J. B. & Young, A. B. Neurosci. Abstr. 9, 264 (1983).
Halpain, S., Parsons, B. & Rainbow, T. C. Bur. J. Pharm. 86, 313–314 (1982).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Monaghan, D., Holets, V., Toy, D. et al. Anatomical distributions of four pharmacologically distinct 3H-L-glutamate binding sites. Nature 306, 176–179 (1983). https://doi.org/10.1038/306176a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/306176a0
This article is cited by
-
Molecular Neurobiology of Lead (Pb2+): Effects on Synaptic Function
Molecular Neurobiology (2010)
-
Mifepristone Repairs Region-Dependent Alteration of Synapsin I in Hippocampus in Rat Model of Depression
Neuropsychopharmacology (2007)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.